I’m going to invest my children’s education in the CVR

Discussion in 'Bristol-Myers Squibb' started by anonymous, Nov 17, 2020 at 7:05 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    IMO Not happening.
     

  2. anonymous

    anonymous Guest

    And what is your opinion worth? You are probably an junior employee at a hedge fund not an employee at BMS.
     
  3. anonymous

    anonymous Guest

    Even if that person is a junior employee at a hedge fund - then he/she is probably better off than being a drone at this asylum.

    Just puttin' it out there Hiram.
     
  4. anonymous

    anonymous Guest

    Come on seriously? There’s maybe 7 working days left in 2020. FDA concentrating on COVID approvals.
     
  5. anonymous

    anonymous Guest

    I, too, can count days on a calendar.
     
  6. anonymous

    anonymous Guest


    Would you like to play now to Double Jeopardy?
     
  7. anonymous

    anonymous Guest

    Apparently we are ramping up manufacturing runs. Approval in a few days?
     
  8. anonymous

    anonymous Guest

    Prove it
     
  9. anonymous

    anonymous Guest

    It’s called Covid. Maybe you never heard of it, but manufacturing has been hampered.
     
  10. anonymous

    anonymous Guest

    Having no skin in the game except being a current employee, I am hoping for approval in early 2021. There’s a lot more this company can do with 9 billion bucks than rewarding ex-CELG employees with even more ridiculous amounts of cash.
     
  11. anonymous

    anonymous Guest

    It is really in the FDA’s hand at this point. Could they get it done this year? Absolutely. Are they likely to get this year? Perhaps. No one knows except the FDA. Will get done in the next 6 week? Almost certainly.
     
  12. anonymous

    anonymous Guest

    CVR bagholder here.

    bristol peeps - let’s get this done ASAP!
     
  13. anonymous

    anonymous Guest

    How do you know it's in the FDA's hands? That would mean Bristol has responded to the 483, if there is one. (I'm not an employee, just an investor).
     
  14. anonymous

    anonymous Guest

    From an employee to an investor - communication here sucks.
     
  15. anonymous

    anonymous Guest

    I wouldn't expect BMS to tell employees very specific details of the liso-cel review given how material the drug is the CVR.
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest